Overview

Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Status:
Completed
Trial end date:
2018-05-21
Target enrollment:
0
Participant gender:
All
Summary
This is a post-marketing surveillance study in Japan that will evaluate the safety and patient satisfaction with GLASH VISTA™ (bimatoprost cutaneous solution 0.03%) in the treatment of hypotrichosis of the eyelashes.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

-Patients who have been prescribed GLASH VISTA™ in clinical settings and filled at least
one prescription for GLASH VISTA™.

Exclusion Criteria:

-None.